Blood Pressure Patterns

Contributions of mean and shape of blood pressure distribution to worldwide trends and variations in raised blood pressure: a pooled analysis of 1018 population-based measurement studies with 88.6 million participants

NCD Risk Factor Collaboration (NCD-RisC)
Members are listed at the end of the paper.

Corresponding author. Prof. Majid Ezzati, Imperial College London, London W2 1PG, UK.
E-mail: majid.ezzati@imperial.ac.uk

Editorial decision 16 January 2018; Accepted 24 January 2018

Abstract

Background: Change in the prevalence of raised blood pressure could be due to both shifts in the entire distribution of blood pressure (representing the combined effects of public health interventions and secular trends) and changes in its high-blood-pressure tail (representing successful clinical interventions to control blood pressure in the hypertensive population). Our aim was to quantify the contributions of these two phenomena to the worldwide trends in the prevalence of raised blood pressure.

Methods: We pooled 1018 population-based studies with blood pressure measurements on 88.6 million participants from 1985 to 2016. We first calculated mean systolic blood pressure (SBP), mean diastolic blood pressure (DBP) and prevalence of raised blood pressure by sex and 10-year age group from 20–29 years to 70–79 years in each study, taking into account complex survey design and survey sample weights, where relevant. We used a linear mixed effect model to quantify the association between (probit-transformed) prevalence of raised blood pressure and age-group- and sex-specific mean blood pressure. We calculated the contributions of change in mean SBP and DBP, and of change in the prevalence-mean association, to the change in prevalence of raised blood pressure.

Results: In 2005–16, at the same level of population mean SBP and DBP, men and women in South Asia and in Central Asia, the Middle East and North Africa would have the highest prevalence of raised blood pressure, and men and women in the high-income Asia Pacific and high-income Western regions would have the lowest. In most region-sex-age groups where the prevalence of raised blood pressure declined, one half or more of the decline was due to the decline in mean blood pressure. Where prevalence of raised blood pressure has increased, the change was entirely driven by increasing mean blood pressure, offset partly by the change in the prevalence-mean association.

© The Author(s) 2018. Published by Oxford University Press on behalf of the International Epidemiological Association.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
**Conclusions:** Change in mean blood pressure is the main driver of the worldwide change in the prevalence of raised blood pressure, but change in the high-blood-pressure tail of the distribution has also contributed to the change in prevalence, especially in older age groups.

**Key words:** Blood pressure, hypertension, population health, global health, non-communicable disease

---

### Key Messages

- After accounting for the difference in mean blood pressure, there is still a 3–5 percentage-point difference in the prevalence of raised blood pressure across regions, being highest in South Asia and in Central Asia, the Middle East and North Africa, and lowest in the high-income Asia Pacific and high-income Western regions.
- Shifts in entire distribution of blood pressure have been the main driver of the change in prevalence of raised blood pressure.
- There is also a measurable contribution from the change in the high-blood-pressure tail of the distribution, towards lowering the prevalence of raised blood pressure, especially in older people.

---

**Introduction**

Raised blood pressure, commonly defined as systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg, is used to identify individuals at high risk of cardiovascular diseases. Globally, one in four men and one in five women, totalling 1.13 billion adults, had raised blood pressure in 2015. One of the global non-communicable disease (NCD) targets adopted by the World Health Organization (WHO) in 2013 is to reduce the prevalence of raised blood pressure by 25% compared with its 2010 level, by 2025.

The prevalence of raised blood pressure varies substantially across and within regions and countries, with age-standardized adult prevalence in 2015 ranging from 20% in the high-income Asia Pacific region to 33% in Central and Eastern Europe for men, and from 11% in the high-income Asia Pacific region to 28% in sub-Saharan Africa for women. Prevalence has declined substantially in high-income regions for decades, and is also declining in some middle-income regions; it has been stable or has increased in other low- and middle-income regions.

Blood pressure is a complex trait, affected by genes, fetal and early childhood nutrition and growth, adiposity and weight gain, diet (especially sodium and potassium intakes), alcohol use, smoking, physical activity, air pollution, lead, noise, psychosocial stress, sleep duration and the use of blood pressure-lowering medicines. Changes in some of these factors, for example increase in body mass index (BMI) and better nutrition in childhood and adolescence, can shift the entire population distribution of blood pressure, and hence change its mean as well as the prevalence of raised blood pressure. In contrast, the use of antihypertensive medicines and lifestyle change to reduce blood pressure in those with elevated levels would reduce the prevalence of raised blood pressure by acting on the high-blood-pressure tail of the distribution, and hence change the shape of the distribution with a relatively small impact on its mean. An important question that can inform strategies for meeting the global target and reducing the burden of raised blood pressure, is to what extent regional differences and changes over time in the prevalence of raised blood pressure are driven by variations in the mean SBP and DBP versus by the shape of the distribution. We used a database of population-based studies with global coverage conducted over three decades to investigate contributions of population mean and high-blood-pressure individuals to worldwide trends and variations in raised blood pressure.

---

**Methods**

**Study design**

We first used population-based data to estimate the association between the prevalence of raised blood pressure, defined as SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, and population mean SBP and DBP among men and women aged 20 to 79 years in nine regions of the world, from 1985 to 2016. We used a linear mixed effect model to quantify the association between the prevalence of raised blood pressure and mean blood pressure. Our statistical model, described below, allowed the prevalence of raised
blood pressure at any level of mean SBP and DBP to differ by age group, region and time period. We then used the fitted association to estimate the contributions of changes in the population mean blood pressure versus changes in the shape of its distribution (represented by how the prevalence-mean association varied over region and time), to the changes in the prevalence of raised blood pressure in different regions.

Data sources
We used data from NCD Risk Factor Collaboration (NCD-RisC) database, which contains studies that had measured blood pressure in representative samples of the national populations or of one or more sub-national regions and communities. NCD-RisC is a worldwide network of health researchers and practitioners whose aim is to document systematically the worldwide trends and variations in NCD risk factors. Our methods for identifying and accessing data sources, and the inclusion and exclusion criteria, are described in recent publications. In summary, the database was collated through multiple routes for identifying and accessing data. We accessed publicly available population-based multi-country and national measurement surveys as well as the WHO STEPwise approach to Surveillance (STEPS) surveys. We requested, via WHO and its regional and country offices, ministries of health and other national health and statistical agencies to identify and access population-based surveys. Requests were also sent via the World Heart Federation to its national partners. We made a similar request to the co-authors of an earlier pooled analysis of cardiometabolic risk factors, and invited them to reanalyse data from their studies and join NCD-RisC. To identify major sources not accessed through the above routes, we searched and reviewed published studies, and invited all eligible studies to join NCD-RisC. Finally, NCD-RisC members are periodically asked to review the list of sources from their country, to suggest additional sources currently not in the database and to verify that the included data from their country meet the inclusion criteria as listed in the Supplementary data (available at IJE online) and that there are no duplicates. Here, we analysed data collected from 1985 to 2016 on men and women aged 20–79 years, in 10-year age groups from 20–29 years to 70–79 years.

Statistical methods
We first calculated mean SBP, mean DBP and prevalence of raised blood pressure for these age groups by sex in each study, taking into account complex survey design and survey sample weights, where relevant. We excluded data points which did not cover complete 10-year age groups, e.g., those in people aged 25–29 years or 60–64 years, to avoid bias in the estimated associations. We also excluded age-sex groups with < 25 participants, because their means and prevalence have larger uncertainty.

We then estimated the relationship between the prevalence of raised blood pressure and mean, using a linear mixed effect model, shown below in the equation (where $\varepsilon$ is the error term), separately by sex. We used probit-transformed prevalence because it provided a better fit to the data than a simple linear model or logit transformation. The model included age group (10-year age groups from 20–29 to 70–79) and the decade when the data were collected (1985–94, 1995–2004 or 2005–16). We also included interactions between age group and mean blood pressure, between decade and mean blood pressure, and among these three terms, which allowed the prevalence-mean association to vary by age group and over time. We included regional random intercepts to account for the differences in prevalence at any level of mean SBP and DBP by region. The regions, used in previous analyses of cardiometabolic risk factors, were: Central and Eastern Europe; Central Asia, the Middle East and North Africa; East and South-east Asia; high-income Asia Pacific; high-income Western countries; Latin America and the Caribbean; Oceania; South Asia; and sub-Saharan Africa. Countries in each region are listed in Supplementary Table 1 (available as Supplementary data at IJE online). The models were fitted in statistical software R version 3.4.2. Goodness of fit of the models was assessed by conditional $R^2$, which represents the proportion of variance explained by both fixed and random factors.

Probit-transformed prevalence of raised blood pressure

\[
\begin{align*}
&= \beta_0 + \beta_1 \text{MeanSBP} + \beta_2 \text{MeanDBP} \\
&+ \beta_3 \text{Age group} + \beta_4 \text{Decade} \\
&+ \beta_5 \text{Age group} \cdot \text{Decade} + \beta_6 \text{MeanSBP} \cdot \text{Age group} \\
&+ \beta_7 \text{MeanDBP} \cdot \text{Age group} \\
&+ \beta_8 \text{MeanSBP} \cdot \text{Decade} + \beta_9 \text{MeanDBP} \cdot \text{Decade} \\
&+ \beta_{10} \text{MeanSBP} \cdot \text{Age group} \cdot \text{Decade} \\
&+ \beta_{11} \text{MeanDBP} \cdot \text{Age group} \cdot \text{Decade} \\
&+ \text{Random intercept}_{\text{Region}} + \varepsilon
\end{align*}
\]
distribution of the regression coefficients for each of the 1000 fitted regressions (i.e. 1 000 000 sets of regression coefficients). We report the median of the resulting 1 000 000 draws for each coefficient, and their 2.5th and 97.5th percentiles as the 95% confidence interval. We also report the median of conditional R$^2$ from the 1000 fitted regressions.

We used the fitted regressions to quantify how much differences across regions, and changes over time in the prevalence of raised blood pressure, were driven by differences in mean SBP and DBP, versus by differences in the prevalence-mean association. We first used the age-sex-specific global mean SBP and DBP in 2010 (mid-point of the 2005–16 period) in the fitted association, and estimated the prevalence of raised blood pressure by region. The age-sex-specific mean SBP and DBP values were taken from a recent comprehensive analysis of worldwide trends in blood pressure, and are listed in the Supplementary Table 2 (available as Supplementary data at IJE online). We report the differences between the predicted regional raised blood pressure prevalence and that of the world as a whole. These differences measure how much prevalence would vary across regions—due to geographical variations in the shape of blood pressure distribution—if they had the same population mean blood pressure.

We then decomposed total change in prevalence of raised blood pressure from 1985–94 to 2005–16 into contributions of change in mean SBP and DBP, change in the shape of prevalence-mean association and interaction of the two. The contribution of change in mean was estimated by allowing mean SBP and DBP for each age, sex and region to change over time, while keeping the decade variable fixed at 1985–94. The contribution of change in association was estimated by setting mean SBP and DBP to their 1990 levels (mid-year of 1985–94) for each age, sex and region, and allowing the decade variable to change. The interaction of the two factors is the difference between total change in prevalence and the sum of the above two components. The three components are schematically shown in Figure 1.

We repeated the above analyses for each of the 1 000 000 sets of regression coefficients. We report the median of the resulting 1 000 000 estimates as our main result and their 2.5th and 97.5th percentiles as the 95% confidence interval. All analyses were done separately for men and women. Results were calculated by 10-year age groups.
and then aggregated into two age bands, 20–49 years and 50–79 years, by taking the weighted average of age-specific results; weights from the WHO standard population were used.

Results

Data sources

We used data from 1018 population-based studies with 88,559,656 participants, of whom 86,187,860 were aged 20–79 years, and satisfied the above inclusion criteria (Supplementary Table 3, available as Supplementary data at IJE online). A total of 385 studies were from the high-income Western region, 108 from East and South-east Asia, 107 from Central Asia, the Middle East and North Africa, 106 from Central and Eastern Europe, 83 from sub-Saharan Africa, 79 from Latin America and the Caribbean, 78 from high-income Asia Pacific, 38 from South Asia and 34 from Oceania. The individual-level data were summarized into 7910 age-sex-specific pairs of mean of and prevalence of raised blood pressure. The number of data sources by country is shown in Figure 2, and a list of data sources and their characteristics is provided in Supplementary Table 4 (available as Supplementary data at IJE online).

Association of prevalence of raised blood pressure with mean SBP and DBP

The coefficients of the regression models are listed in Supplementary Tables 5 and 6 (available as Supplementary data at IJE online). Together, mean SBP and DBP, decade, age group and region explained most of the variation in the prevalence of raised blood pressure, evidenced by the high conditional R² statistics of 0.918 for women and 0.871 for men.

Changes in prevalence of raised blood pressure and mean SBP and DBP, by region

In 2005–16, the age-standardized prevalence of raised blood pressure in people aged 20–49 years ranged from 4% (95% credible interval: 3–6%) in high-income Asia Pacific to 16% (13–19%) in sub-Saharan Africa in women, and from 14% (11–17%) in high-income Asia Pacific to 25% (21–30%) in Central and Eastern Europe in men. In those aged 50–79 years, the range was from 31%
(26–36%) in high-income Asia Pacific to 56% (52–61%) in sub-Saharan Africa in women, and from 40% (36–43%) in the high-income Western region to 57% (51–63%) in Central and Eastern Europe in men.

The prevalence of raised blood pressure decreased substantially from 1985–94 to 2005–16 in the two high-income regions and Central and Eastern Europe in both men and women across all ages (Figure 3). It also decreased in Latin America and the Caribbean, and in Central Asia, the Middle East and North Africa, and marginally in men in sub-Saharan Africa. Over the same period, mean SBP and mean DBP decreased in these regions and sexes, except in men in sub-Saharan Africa, whose mean SBP and DBP increased, and in men in Central Asia, the Middle East and North Africa, whose mean SBP and DBP were unchanged. The prevalence of raised blood pressure and mean SBP and DBP increased in Oceania and South Asia.

Contributions of mean and shape of blood pressure distribution to regional variations in raised blood pressure

Although in 2005–16 the ranking of regions in terms of prevalence of raised blood pressure was largely the same as...
the ranking of the mean, especially for women, inter-region differences in prevalence were not entirely due to those of mean blood pressure. Rather, some regions had an excess prevalence compared with what would be expected based on their mean, and others a lower prevalence compared with what would be expected based on their mean. At the same level of population mean SBP and DBP as that of the world as a whole, men and women in South Asia and in Central Asia, the Middle East and North Africa would have the highest prevalence of raised blood pressure, about 1–2 percentage points higher than the world average in different age groups (Figure 4). In contrast, at the same level of population mean SBP and DBP as that of the world as a whole, high-income Asia Pacific would have the lowest prevalence, followed by the high-income Western region, with prevalence about 1–3 percentage points lower than the world average across different age and sex groups, especially among women. The

Figure 4. Regional differences in prevalence of raised blood pressure among men and women aged 20–49 years and 50–79 years in 2005–16 if every region had the same mean SBP and DBP, equal to the global age-sex-specific mean in 2010. The points show the central estimates and the bars their 95% confidence intervals.
ordering of regions in terms of excess prevalence was similar between men and women, except for men in Central and Eastern Europe whose ranking in terms of excess prevalence was worse than that of women in the same region.

Contributions of mean and shape of blood pressure distribution to trends in raised blood pressure

In most regions where sex and age groups experienced a decline in the prevalence of raised blood pressure, the decline in mean blood pressure was the main driver of the decline in prevalence (Figure 5). The main exceptions to this distributional shift were men in sub-Saharan Africa and in Central Asia, the Middle East and North Africa, whose mean blood pressure increased or remained unchanged while prevalence declined slightly. Further, in men in Latin America and the Caribbean and in Central and Eastern Europe, change in prevalence-mean association contributed marginally more to prevalence decline than did the decline in mean blood pressure. Elsewhere, the decline in mean blood pressure accounted for 60% or more of the decline in the prevalence of raised blood pressure, with a larger contribution where mean blood pressure declined more, typically in high-income regions. Change in the prevalence-mean association, which represents change in the high-blood-pressure tail of the distribution, was responsible for the majority of the remainder of change in prevalence, and for its entirety among men in sub-Saharan Africa and in Central Asia, the Middle East and North Africa. The contribution of change in prevalence-mean association was larger in those aged 50–79 years than in those aged 20–49 years in most regions, especially for women.

The prevalence of raised blood pressure increased among men and women in Oceania and South Asia, and among women in sub-Saharan Africa and men in East and South-east Asia. The increase was driven entirely by rise in mean blood pressure, offset partly by the change in the prevalence-mean association. Prevalence of raised blood pressure remained largely unchanged among women in East and South-east Asia, due to opposing effects of

Figure 5. Contributions of change in mean blood pressure, change in prevalence-mean association, and the interaction of the two, to change in prevalence of raised blood pressure from 1985–94 to 2005–16 by region, sex and age group.
increasing mean and the decrease brought by the changes in prevalence-mean association.

Discussion

We found that the trends and geographical variations in the prevalence of raised blood pressure are largely driven by shifts in the distribution of blood pressure in whole populations, rather than by the shape of the distribution. There was nonetheless an important contribution from having fewer high-blood-pressure individuals at the same level of population mean SBP and DBP over time, especially in older age groups.

Rose and Day and Laaser et al. used data from the Intersalt Study and from population-based studies in Germany, respectively, and found a strong association between prevalence of raised blood pressure and its mean, as we did, but neither analysis had sufficient data to quantify how the association varied in relation to age, time period or region as was done here. An analysis of data from the multi-country MONICA Project found that the upper percentiles of blood pressure distribution changed as much as its mean in some communities, and by a larger amount in others. The authors concluded that the decline in blood pressure is mostly a population phenomenon but there was no detailed quantification of the contribution, especially in relation to age, time period or region as was done here with substantially more data. Downward shifts in the whole blood pressure distribution over time have also been reported in a few high-income countries, with some studies also finding a larger decline in the upper tail than in the mean of the blood pressure distribution, which is consistent with our results.

The strengths of our study include presenting the first global analysis of how much population mean and high-blood-pressure individuals have contributed to worldwide trends and variations in raised blood pressure, using a large global database with data from different regions and over time, and using methods that allowed the prevalence-mean association to vary by sex, age group, time period and region. Despite using the most comprehensive global collection of population-based studies to date, some regions had limited data, especially early in our analysis period. Further, there have been changes over time in devices used for measuring blood pressure in health surveys, with standard mercury sphygmomanometers replaced by random-zero sphygmomanometers and more recently digital oscillometric devices. These changes are unlikely to have affected our regional comparisons, and would only affect prevalence-mean association over time if they had differential effects at high versus low blood pressure.

Although we found that changes in the prevalence of raised blood pressure have been mostly due to whole-distribution shifts, the behavioural, nutritional and environmental drivers of this shift remain uncertain. In high-income countries, the decline in blood pressure has occurred despite the rise in BMI, which is an established risk factor for high blood pressure, but how the concurrent and at times larger rise in BMI in low- and middle-income countries may be affecting blood pressure is unclear. Salt intake has declined in China and possibly in some high-income countries but has not changed in other countries where blood pressure has declined. Similarly, prevalence of smoking has declined in most high-income countries and in some middle-income countries but remains high or is increasing in other low- and middle-income regions. Alcohol consumption has also had mixed trends across countries and regions. Other potential population-wide drivers of the decline in mean blood pressure which tend to improve with social and economic development include year-round availability of fruits and vegetables, which might increase the amount and regularity of their consumption; central heating at home and work which would lower winter blood pressure; and improvements in early childhood and adolescent nutrition, as seen in greater height in successive birth cohorts when they reach adulthood. A role for such distal determinants with life course impacts is strengthened by the fact that blood pressure is also decreasing in adolescents in high-income countries and possibly some middle-income countries.

Whereas these determinants act to lower mean blood pressure, better developed health systems are more effective in identifying and treating high-blood-pressure individuals, which would change the tail of the distribution without a major impact on its mean. The role of treatment in reducing the prevalence of high blood pressure has become increasingly important as clinical guidelines have lowered the threshold for diagnosing and treating hypertension, e.g. from having an SBP of 160 mmHg or DBP of 95 mmHg in the 1970s to an SBP of 140 mmHg or DBP of 90 mmHg and to an SBP of 130 mmHg or DBP of 80 mmHg in the newly released ACC/AHA guidelines. Over time, regional and international guidelines for diagnosis and treatment of hypertension, which are evaluated as cost-effective, have been developed and a larger share of people with raised blood pressure are treated in high-income countries and in some middle-income countries. Nonetheless, treatment coverage and effectiveness remain low, especially in low-income settings. Further, there have been improvements in effectiveness of treatment over time, leading to better control of those with hypertension. It may also be the case that changes in some risk factors, e.g. lower salt intake, have larger benefits for people whose blood pressure is high compared with those with low blood pressure.
pressure, hence changing the high-blood-pressure tail of the distribution as well as its mean.

Our results demonstrate that changes in blood pressure both at the population and at the individual level have contributed to lowering raised blood pressure. What factors have spurred the former over the past few decades, however, remain largely unclear, and may be related to societal changes in nutrition, housing and health systems arising from social and economic development and technological progress. They also demonstrate the need for data that go beyond identifying the causes of low or high blood pressure, but also help measure how these factors change over time in worldwide populations. Learning about these factors would inform programmes that can help reverse the rise in the prevalence of raised blood pressure or accelerate its decline in low- and middle-income nations, where prevalence remains the highest, more effectively.

Supplementary Data

Supplementary data are available at IJE online.

Funding

This work was supported by the Wellcome Trust [101506/Z/13/Z].

Acknowledgement

We thank WHO country and regional offices and the World Heart Federation for support in data identification and access.

Contributors

M.E. designed the study and oversaw research. Members of the Country and Regional Data Group collected and re-analysed data, and checked pooled data for accuracy of information about their study and other studies in their country. Members of the Pooled Analysis and Writing Group collated data, checked all data sources in consultation with the Country and Regional Data Group, and prepared results. B.Z. analysed data and prepared results. B.Z. and M.E. wrote the first draft of the report, with input from other members of the Pooled Analysis and Writing Group. Members of the Country and Regional Data Group commented on draft report. B.Z. is the guarantor for the paper.

Conflict of interest: M.E. received a charitable grant from the Youth Health Programme of AstraZeneca, and personal fees from Third Bridge, Scor and Prudential, outside the submitted work. M.W. received personal fees from Amgen, outside the submitted work. All other authors declare no competing financial interests.

References


NCD Risk Factor Collaboration (NCD-RisC)

Pooled Analysis and Writing

Bin Zhou (Imperial College London, UK); James Bentham (University of Kent, UK; Imperial College London, UK); Mariachiara Di Cesare (Middlesex University, UK); Honor Bixby (Imperial College London, UK); Goodarz Danaei (Harvard TH Chan School of Public Health, USA); Kaveh Hajifathalian (Cleveland Clinic, USA); Cristina Taddei (Imperial College London, UK); Rodrigo M Cable-Larco (Universidad Peruana Cayetano Heredia, Peru); Shirin Djalalinia (Tehran University of Medical Sciences, Iran); Ministry of Health and Medical Education, Iran; Shahab Khatibzadeh (Brandenburg University, Germany); Gregor Starc (University of Zagreb, Croatia); Gregor Starc (University of Ljubljana, Slovenia); Johan Sundström (Uppsala University, Sweden); Mark Woodward (University of New South Wales, Australia; University of Oxford, UK); Majid Ezzati (Imperial College London, UK)

Country and Regional Data

(* equal contribution; listed alphabetically)

Leandra Abarca-Gómez (Caja Costarricense de Seguro Social, Costa Rica)*; Ziad A Abdeen (Al-Quds University, Palestine)*; Niveen M Abu-Rmeileh (Birzeit University, Palestine)*; Benjamin Acosta-Cazares (Instituto Mexicano del Seguro Social, Mexico)*; Robert J Adams (The University of Adelaide, Australia)*; Wichai Aekplakorn (Mahidol University, Thailand)*; Kasar Afsana (BRAC, Bangladesh)*; Carlos A Aguilar-Salinas (Instituto Nacional de Ciencias Medicas y Nutricion, Mexico)*; Charles Agyemang (University of Amsterdam, The Netherlands)*; Noor Ani Ahmad (Ministry of Health Malaysia, Malaysia)*; Alireza Ahmadvand (Non-Communicable Diseases Research Center, Iran)*; Wolfgang Ahrens (Leibniz Institute for Prevention Research and Epidemiology - BIPS, Germany)*; Kamel Ajlouni (National Center for Diabetes and Endocrinology, Jordan)*; Nazgul Akhtaeva (Kazakh National Medical University, Kazakhstan)*; Rajaa Al-Raddadi (King Abdulaziz University, Saudi Arabia)*; Mohamed M Ali (World Health Organization, Switzerland)*; Osman Ali (Universiti Malaysia Sabah, Malaysia)*; Ala’a Alkerwi (Luxembourg Institute of Health, Luxembourg)*; Eman Aly (World Health Organization Regional Office for the Eastern Mediterranean, Egypt)*; Deepak N Amarapurkar (Bombay Hospital and Medical Research Centre, India)*; Philippe Amouyel (Lille University and Hospital, France)*; Antoinette Amuzu (London School of Hygiene & Tropical Medicine, UK)*; Lars Bo Andersen (Western Norway University of Applied Sciences, Norway)*; Sigmund A Andersen (Norwegian School of Sport Sciences, Norway)*; Lars H Angquist (Bispebjerg and Frederiksberg Hospitals, Denmark)*; Ranjit Mohan Anjana (Madras Diabetes Research Foundation, India)*; Daniel Ansong (Komfo Anokye Teaching Hospital, Ghana)*; Hajer Aounallah-Skhiri (National Institute of Public Health, Tunisia)*; Joana Araújo (Universidade do Porto, Portugal)*; Inger Ariansen (Norwegian Institute of Public Health, Norway)*; Tahir Aris (Ministry of Health Malaysia, Malaysia)*; Nimmathota Arlappa (National Institute of Nutrition, India)*; Dominique Arveier (Strasbourg University and Hospital, France)*; Krishna K Aryal (Nepal Health Research Council, Nepal)*; Thor Aspelund (University of Iceland, Iceland)*; Felix K Assah (University of Yaoundé 1, Cameroon)*; Maria Cecilia F Assunção (Federal University of Pelotas, Brazil)*; Maria Avdicová (Regional Authority of Public Health, Banska Bystrica, Slovakia)*; Ana Avevedo (University of Porto Medical School, Portugal)*; Fereidoun Azizi (Shahid Beheshti University of Medical Sciences, Iran)*; Bontha V Babu (Indian Council of Medical Research, India)*; Suhad Bahiery (King Abdulaziz University, Saudi Arabia)*; Magda Balkrishna (National Institute of Nutrition, India)*; Mohamed Bamooshmoos (University of Science and Technology, Yemen)*; Maciej Banach (Medical University of Lodz, Poland)*; Piotr Bandosz (Medical University of Gdansk, Poland)*; José R Banegas (Universidad Autónoma de Madrid, Spain)*; Carlo M Barbagallo (University of Palermo, Italy)*; Alberto Barceló (Pan American Health Organization, USA)*; Amina Barkat (Université Mohammed V de Rabat, Morocco)*; Aluisio JD Barros (Federal University of Pelotas, Brazil)*; Mauro V Barros (University of Pernambuco, Brazil)*; Iqbal Bata (Dalhousie University, Canada)*; Anwar M Batieha (Jordan University of Science and Technology, Jordan)*; Assem Bekbeh (Kazakh National Medical University, Kazakhstan)*; Louise A Baur (University of Sydney, Australia)*; Robert Beaglehole (University of Auckland, New Zealand)*; Habifa Ben Romdhane (University Tunis El Manar,
Michel Paccaud (Institute for Social and Preventive Medicine, Switzerland)*; Cristina Padez (University of Coimbra, Portugal)*; Elena Pahomova (University of Latvia, Latvia)*; Andrezj Pajak (Jagiellonian University Medical College, Poland)*; Domenico Palli (Cancer Prevention and Research Institute, Italy)*; Luigi Palmieri (Istituto Superiore di Sanità, Italy)*; Wenh-Han Pan (Academia Sinica, Taiwan)*; Songhomitra Panda-Jonas (Ruprecht-Karls-Univeristsyt of Heidelberg, Germany)*; Francesco Panza (IRCCS Casa Sollievo della Sofferenza, Italy)*; Dimitrios Papandreou (Zayed University, UAE)*; Soon-Woo Park (Catholic University of Daegu, Republic of Korea)*; Winsome R Parnell (University of Otago, New Zealand)*; Mahboubeh Parsaeian (Tehran University of Medical Sciences, Iran)*; Nikhil D Patel (Jivaneed Hospital, India)*; Ivan Pecin (University of Zagreb School of Medicine, Croatia; University Hospital Centre Zagreb, Croatia)*; Mangesh S Pednekar (Healis-Sekhsaria Institute for Public Health, India)*; Nasheeta Peer (South African Medical Research Council, South Africa)*; Petra H Peeters (University Medical Center Utrecht, The Netherlands)*; Sergio Viana Peixoto (Oswaldo Cruz Foundation René Rachou Research Institute, Brazil)*; Markku Peltonen (National Institute for Health and Welfare, Finland)*; Alexandre C Pereira (Heart Institute, Brazil)*; Annette Peters (Helmholz Zentrum Muenchen, Germany)*; Janina Petkeviciene (Lithuanian University of Health Sciences, Lithuania)*; Nilofar Peykari (Ministry of Health and Medical Education, Iran)*; Son Thai Pham (Vietnam National Heart Institute, Vietnam)*; Iris Pigeot (Leibniz Institute for Prevention Research and Epidemiology - BIPS, Germany)*; Hynek Pikhart (University College London, UK)*; Aida Pilav (University of Sarajevo, Bosnia and Herzegovina)*; Lorenza Pilotto (Cardiovascular Prevention Centre Udine, Italy)*; Freda Pitakaka (Ministry of Health and Medical Services, Solomon Islands)*; Aleksandra Piwonska (The Cardinal Wyszynski Institute of Medical Services, Solomon Islands)*; Rajendra Pradeepa (Madras Diabetes Research Foundation, India)*; Mathur Prashant (Indian Council of Medical Research, India)*; Jacqueline F Price (University of Edinburgh, UK)*; Mathur Prashant (Indian Council of Medical Research, India)*; Mathur Prashant (Indian Council of Medical Research, India)*; Jacqueline F Price (University of Edinburgh, UK)*; Mathur Prashant (Indian Council of Medical Research, India)*; Jacqueline F Price (University of Edinburgh, UK)*; Jardina J Puder (Lausanne University Hospital, Switzerland)*; Maria Puiu (Victor Babes University of Medicine and Pharmacy Timisoara, Romania)*; Margus Punab (Victor Babes University of Medicine and Pharmacy Timisoara, Romania)*; Mostafa Qorbani (Alborz University of Medical Sciences, Iran)*; Tran Quoc Bao (Ministry of Health, Vietnam)*; Ivana Radic (University of Novi Sad, Serbia)*; Ricardas Radiauskas (Lithuanian University of Health Sciences, Lithuania)*; Mahfuzar Rahman (BRAC, Bangladesh)*; Olli Raitakari (University of Turku, Finland)*; Manu Raj (Amrita Institute of Medical Sciences, India)*; Sudha Ramachandra Rao (National Institute of Epidemiology, India)*; Ambaday Ramachandran (India Diabetes Research Foundation, India)*; Elisabete Ramos (University of Porto Medical School, Portugal)*; Lekhraj Rampal (University Putra Malaysia, Malaysia)*; Sanjay Rampal (University of Malaya, Malaysia)*; Daniel A Rangel Reina (Gorgas Memorial Institute of Health Studies, Panama)*; Josep Redon (University of Valencia, Spain)*; Paul Ferdinand M Reganit (University of the Philippines, Philippines)*; Robespierre Ribeiro (Minas Gerais State Secretariat for Health, Brazil)*; Elio Riboli (Imperial College London, UK)*; Fernando Rigo (Health Center San Agustin, Spain)*; Tobias F Rinke de Wit (PharmAccess Foundation, The Netherlands)*; Raphael M Ritti-Dias (Universidade Nove de Julho, Brazil)*; Sian M Robinson (University of Southampton, UK)*; Cynthia Robitaille (Public Health Agency of Canada, Canada)*; Fernando Rodriguez-Arteajo (Universidad Autonoma de Madrid, Spain)*; Maria del Cristo Rodriguez-Perez (Canarian Health Service, Spain)*; Laura A Rodriguez-Villamizar (Universidad Industrial de Santander, Colombia)*; Rosalba Rojas-Martinez (Instituto Nacional de Salud Publica, Mexico)*; Dora Romaguera (CIBEROBN, Spain)*; Kimmo Ronkainen (University of Eastern Finland, Finland)*; Annika Rosengren (University of Gothenburg, Sweden)*; Joel GR Roy (Statistics Canada, Canada)*; Adolfo Rubinstein (Institute for Clinical Effectiveness and Health Policy, Argentina)*; Blanca Sandra Ruiz-Beutancourt (Instituto Mexicano del Seguro Social, Mexico)*; Marcin Rutkowski (Medical University of Gdansk, Poland)*; Charumathi Sabanayagam (Singapore Eye Research Institute, Singapore)*; Harshpal S Sachdev (Sitaram Bhartia Institute of Science and Research, India)*; Olfa Saidi (University Tunis El Manar, Tunisia)*; Sibel Sakarya (Marmara University, Turkey)*; Benoit Salanave (French Public Health Agency, France)*; Eduardo Salazar Martinez (National Institute of Public Health, Mexico)*; Diego Salmeron (CIBER de Epidemiología y Salud Pública, Spain)*; Veikko Salomaa (National Institute for Health and Welfare, Finland)*; Jukka T Salonen (University of Helsinki, Finland)*; Massimo Salvetti (University of Brescia, Italy)*; Jose Sanchez-Abanto (National Institute of Health, Peru)*; Susana Sans (Catalan Department of Health, Spain)*; Diana A Santos (Universidade de Lisboa, Portugal)*; Ina S Santos (Federal University of Pelotas, Brazil)*; Renata Nunes dos Santos (University of Sao Paulo Clinics Hospital, Brazil)*; Rute Santos (University of Porto, Portugal)*; Jouko L Saramies (South Karelia Social and Health Care District, Finland)*; Luis B Sardinha (Universidade de Lisboa, Portugal)*; Giselle Sarganas (Robert Koch Institute, Germany)*; Nizal Sarrafzadehgan (Isfahan Cardiovascular Research Center, Iran)*; Kai-Uwe Saum (German Cancer Research Center, Germany)*;
Savvas Savva (Research and Education Institute of Child Health, Cyprus); Marcia Scazufca (University of Sao Paulo Clinics Hospital, Brazil); Herman Schargrodsky (Hospital Italiano de Buenos Aires, Argentina); Sabine Schipf (University Medicine of Greifswald, Germany); Carsten O Schmidt (University Medicine of Greifswald, Germany); Ben Schöttler (German Cancer Research Center, Germany); Constance Schultsz (Academic Medical Center of University of Amsterdam, The Netherlands); Alette E Schutte (South African Medical Research Council, South Africa; North-West University, South Africa); Aye Aye Sein (Ministry of Health, Myanmar); Abhijit Sen (Norwegian University of Science and Technology, Norway); Idowu O Senbanjo (Lagos State University College of Medicine, Nigeria); Sadaf G Sepanlou (Tehran University of Medical Sciences, Iran); Sanjib K Sharma (B P Koirala Institute of Health Sciences, Nepal); Jonathan E Shaw (Baker Heart and Diabetes Institute, Australia); Kenji Shibuya (The University of Tokyo, Japan); Dong Wook Shin (Samsung Medical Center, Republic of Korea); Youhan Shin (Singapore Eye Research Institute, Singapore); Khairil Si-Ramlee (Ministry of Health, Brunei); Rosalynn Siantar (Singapore Eye Research Institute, Singapore); Abla M Sibai (American University of Beirut, Lebanon); Diego Augusto Santos Silva (Federal University of Santa Catarina, Brazil); Mary Simon (India Diabetes Research Foundation, India); Judith Simons (St Vincent’s Hospital, Australia); Leon A Simons (University of New South Wales, Australia); Michael Sjöström (Karolinska Institutet, Sweden); Sine Skovbjerg (Bispebjerg and Frederiksberg Hospital, Denmark); Jolanta Slowikowska-Hilczer (Medical University of Lodz, Poland); Przemyslaw Slusarczyk (International Institute of Molecular and Cell Biology, Poland); Liam Smeeth (London School of Hygiene & Tropical Medicine, UK); Margaret C Smith (University of Oxford, UK); Marieke B Snijder (Academic Medical Center Amsterdam, The Netherlands); Hung-Kwan So (University of Hong Kong, China); Eugene Sobngwi (University of Yaoundé 1, Cameroon); Stefan Söderberg (Umeå University, Sweden); Vincenzo Solfrizzi (University of Bari, Italy); Emily Sonestedt (Lund University, Sweden); Yi Song (Peking University, China); Thorkild IA Sørensen (University of Copenhagen, Denmark); Maroje Soric (University of Zagreb, Croatia); Charles Sossa Jérôme (Institut Régional de Santé Publique, Benin); Aicha Soumatre (University of Bordeaux, France); Jan A Staessen (University of Leuven, Belgium); Gregor Starc (University of Ljubljana, Slovenia); Maria G Statthopoulou (INSERM, France); Bill Stavreski (Heart Foundation, Australia); Jostein Steene-Johannessen (Norwegian School of Sport Sciences, Norway); Peter Stehle (Bonn University, Germany); Aryeh D Stein (Emory University, USA); George S Stergiou (Sotiria Hospital, Greece); Jochanan Stessman (Hadassah University Medical Center, Israel); Jutta Stieber (Helmholz Zentrum München, Germany; deceased); Doris Stöckl (Helmholz Zentrum München, Germany); Tanja Stocks (Lund University, Sweden); Jakub Stokowski (National Institute of Public Health-National Institute of Hygiene, Poland); Karien Stronks (University of Amsterdam, The Netherlands); Maria Wany Struulfeld (Federal University of São Paulo, Brazil); Chien-An Sun (Fu Jen Catholic University, Taiwan); Johan Sundström (Uppsala University, Sweden); Yn-Tz Sung (The Chinese University of Hong Kong, China); Paibul Suriyawongpaisal (Mahidol University, Thailand); Rody G Sy (University of the Philippines, Philippines); E Shyong Tai (National University of Singapore, Singapore); Mari-Liis Tammasoo (University of Tartu, Estonia); Abdonas Tamosiunas (Lithuanian University of Health Sciences, Lithuania); Eng Joo Tan (University of Sydney, Australia); Xun Tang (Peking University, China); Frank Tanser (University of KwaZulu-Natal, South Africa); Yong Tao (Peking University, China); Mohammed Rasoul Tarawneh (Ministry of Health, Jordan); Carolina B Tarqui-Mamani (National Institute of Health, Peru); Oana-Florentina Tatu (Carol Davila University of Medicine and Pharmacy, Romania); Anne Taylor (The University of Adelaide, Australia); Holger Theobald (Karolinska Institutet, Sweden); Xenophon Theodoridis (Alexander Technological Educational Institute, Greece); Lurgarde Thijs (University of Leuven, Belgium); Betina H Thuesen (Bispebjerg and Frederiksberg Hospital, Denmark); Anne Tjønneland (Danish Cancer Society Research Centre, Denmark); Hanna K Tononen (National Institute for Health and Welfare, Finland); Janne S Tolstrup (University of Southern Denmark, Denmark); Murat Tophas (Karadeniz Technical University, Turkey); Roman Topó-Madry (Jagiellonian University Medical College, Poland); Maria José Torno (Health Service of Murcia, Spain); Maties Torrent (IB-SALUT Area de Salut de Menorca, Spain); Pierre Traissac (Institut de Recherche pour le Développement, France); Dimitrios Trichopoulos (Harvard TH Chan School of Public Health, USA); deceased); Antonia Trichopoulos (Hellenic Health Foundation, Greece); Oanh TH Trinh (The University of Pharmacy and Medicine of Ho Chi Minh City, Vietnam); Atul Trivedi (Government Medical College, India); Lechaba Tshepo (Sefako Makgatho Health Science University, South Africa); Marshall K Tulloch-Reid (The University of the West Indies, Jamaica); Fikru Tullu (Addis Ababa University, Ethiopia); Tomi-Pekka Tuomainen (University of Eastern Finland, Finland); Jaakko Tuomilehto (Danish Diabetes Institute, Kuwait); Maria L Turley (Ministry of Health, New Zealand); Per Tynelius (Karolinska Institutet, Sweden); Christophe Tzourio (University of Bordeaux, France); Peter Ueda (Harvard TH Chan School of Public Health, USA); Eunice E Ugel (Universidad Centro-Occidental Lisandro Alvarado, Venezuela); Hanno Ulmer (Medical University of Innsbruck, Austria); Hannu MT Uusitalo (University of Tampere Tays Eye Center, Finland); Gonzalo Valdivia (Pontificia Universidad...